Sarepta Therapeutics faced a 36% stock drop following the death of a third patient treated with its gene therapies for muscular dystrophies. The latest fatality involved a 51-year-old man with limb-girdle muscular dystrophy participating in the Phase I DISCOVERY trial of SRP-9004. Sarepta attributed deaths to acute liver failure and declined an FDA request to halt shipments of its Duchenne muscular dystrophy therapy Elevidys. The company is pausing some development activities amid safety concerns.